Table 7.
Immunotherapies in clinical trials for AD (clinicaltrials.gov accessed 1/5/2017)
| Agent | Sponsor | Target | Trial phase | Population |
|---|---|---|---|---|
| AADvac1 | Axon Neuroscience | Anti-tau mAb | 1 | AD |
| AADvac1 | Axon Neuroscience | Anti-tau mAb | 2 | Mild-moderate AD |
| ABBV-8E12 | AbbVie | Anti-tau mAb | 2 | Early AD |
| Aducanumab | Biogen | mAb targeting multiple forms of Aβ | 1 | Healthy volunteers |
| Aducanumab | Biogen | mAb targeting multiple forms of Aβ | 1 | Prodromal-mild AD |
| Aducanumab | Biogen | mAb targeting multiple forms of Aβ | 1 | Mild-moderate AD |
| Aducanumab | Biogen | mAb targeting multiple forms of Aβ | 3 | Early AD |
| Aducanumab | Biogen | mAb targeting multiple forms of Aβ | 3 | Early AD |
| Albumin and immunoglobulin | Grifols | Polyclonal antibody targeting multiple forms of Aβ | 3 | Mild-moderate AD |
| BAN2401 | Eisai | mAb targeting N terminal protofibrils | 2 | Early AD |
| CAD106 | Novartis, NIA | Aβ1–6, active vaccine | 2 | AD, at risk |
| Crenezumab | Genentech | mAb targeting soluble oligomer and fibrillar Aβ | 1 | Mild-moderate AD |
| Crenezumab | Genentech, NIA, Academic | mAb targeting soluble oligomer and fibrillar Aβ | 2 | ADAD |
| Crenezumab | Genentech | mAb targeting soluble oligomer and fibrillar Aβ | 3 | Prodromal-mild AD |
| Gantenerumab | Roche | mAb targeting aggregated Aβ | 3 | Mild AD |
| Gantenerumab | Roche | mAb targeting aggregated Aβ | 3 | Prodromal AD |
| Gantenerumab | Roche, Lilly, Alzheimer's Association | mAb targeting aggregated Aβ | 2/3 | AD, at risk |
| Solanezumab | Lilly, Roche, Alzheimer's Association | mAb targeting monomeric Aβ | 2/3 | AD, at risk |
| KH6640 | Kyowa Hakko Kirin | mAb targeting aggregated Aβ | 1 | AD |
| Lu AF20513 | Lundbeck | 1 | Mild AD | |
| NewGam 10% IVIG | Sutter Health | Polyclonal antibody targeting multiple forms of Aβ | 2 | Amnestic MCI |
| LY2599666 & solanezumab | Lilly | Combination of BACE inhibitor and MAb targeting monomeric Aβ | 1 | MCI due to AD |
| LY3303560 | Lilly | 1 | MCI due to AD-mild AD | |
| LY30032813 | Lilly | 1 | MCI due to AD | |
| LY30032813 | Lilly | 1 | Mild-moderate AD | |
| RO7105705 | Genentech | Anti-tau mAb | 1 | Mild-moderate AD |
| Solanezumab | Lilly | mAb targeting monomeric Aβ | 3 | Prodromal AD |
| Solanezumab | Lilly | mAb targeting monomeric Aβ | 3 | Preclinical AD |
| Solanezumab | Lilly | mAb targeting monomeric Aβ | 3 | AD |
| Solanezumab | Lilly | mAb targeting monomeric Aβ | 3 | Mild AD |
| UB-311 | United Neuroscience | mAb targeting N terminal Aβ1–14 | 2 | Mild AD |
Abbreviations: AD, Alzheimer's disease; ADAD, autosomal dominant Alzheimer's disease; mAb, monoclonal antibody; MCI, mild cognitive impairment Yes, the expansion is correct.; IVIG, intravenous immunoglobulin; NIA, National Institute on Aging.